Supplementary Materials:

Materials and Methods:
M. tuberculosis filter culture and metabolite extraction M. tuberculosis H37Rv was cultured in a biosafety level 3 facility at 37 °C in Middlebrook 7H9 broth (m7H9) or on 7H10 agar (m7H10) (Difco) supplemented with 0.2% glucose, 0.05% glycerol, 0.04% Tyloxapol, 0.5 g/l bovine serum albumin and 0.085% NaCl. M. tuberculosisladen filters used for MIC determinations and metabolomic profiling were generated as previously described (8, 22) and incubated at 37°C for 5 days to reach the midlogarithimic phase of growth. Briefly, M. tuberculosis was first grown in m7H9 until the late logarithmic phase and then inoculated onto 22 mm 0.22 μm nitrocellulose filters under vacuum filtration. M. tuberculosis-laden filters were then placed atop chemically equivalent m7H10 agar media (described above) and allowed to grow at 37 o C. M. tuberculosis-laden filters were transferred on day 5 to chemically identical media containing drugs or dimethylsulfoxide vehicle as indicated. MICs were determined by using the same bacterial inoculum size as for metabolomic profiling experiments and identifying the drug concentration needed to suppress visible growth after 14 days of incubation atop drug impregnated agar media. 
Liquid chromatography-coupled mass spectrometry
Extracted metabolites were separated on a Cogent Diamond Hydride Type C column (Gradient 3) (23) . The mobile phase consisted of the following: solvent A (ddH 2 O with 0.2% acetic acid) and solvent B (acetonitrile with 0.2% acetic acid). The gradient used was as follows: 0-2 min, 85% B; 3-5 min, 80% B; 6-7 min, 75%; 8-9 min, 70% B; 10-11.1 min, 50% B; 11.1-14 min 20% B; 14.1-24 min 5% B followed by a 10 min re-equilibration period at 85% B at a flow rate of 0.4 ml/min. The mass spectrometer used was an Agilent Accurate Mass 6220 TOF coupled to an Agilent 1200 LC system. Dynamic mass axis calibration was achieved by continuous infusion of a reference mass solution using an isocratic pump with a 100:1 splitter. This configuration achieved mass errors of 5 ppm, mass resolution ranging from 10,000 to 25,000 (over m/z 121-955 atomic mass units (AMU)), and 5 log 10 dynamic range. Detected ions were deemed metabolites on the basis of unique accurate mass-retention time identifiers for masses exhibiting the expected distribution of accompanying isotopomers and authentic chemical standards. Metabolite identities were searched for using a mass tolerance of <0.005 Da. Metabolites were quantified using a calibration curve generated with chemical standard spiked into homologous mycobacterial extract to correct for matrix-associated ion suppression effects.
Enzyme assays
FolP1 from M. tuberculosis was cloned, expressed and purified as previously described (11). 6-Hydroxymethyl-7,8-dihydropterin pyrophosphate (H 2 PtePP) substrate was chemically reduced according to literature methods (24) from 6-hydroxymethyl-7,8-pterin pyrophosphate (Schircks Laboratories). FolP1 activity was measured by high performance liquid chromatographic analysis. Reactions contained 50 mM Tris pH 7.5, 5 mM MgCl 2 , 1 mM dithiothreitol, 10 μM H 2 PtePP (excess), 50 nM FolP1 and varying PABA or PAS. Reactions were initiated by addition of enzyme. Reactions were incubated at 25 °C prior to quenching with 50 mM (final) EDTA. Data were collected using a Phenomenex Luna(2) 2 x 50mm 3μm 100Å C 18 column on an Agilent 1100 LC-MS instrument. Samples were eluted with a gradient of 95% Solvent A (0.1% formic acid in water), 5% Solvent B (0.1% formic acid in acetonitrile) to 5% A, 95 % B in 10 min (0.3 mL/min). Product formation was determined by comparing peak area of H 2 Pte or H 2 PtePAS formed (A 284 ) and comparing to a standard curve to determine concentration. Data were fit to the Michaelis-Menten equation to determine k cat and K M values.
FolC from M. tuberculosis was cloned, expressed, and purified as previously described (25), modified by the use of unaltered pET-42a vector (Novagen) and pGro7 (Takara) chaperones. H 2 Pte (dihydropteroate) was enzymatically synthesized: reactions contained 1.2 μM FolP1, 40 mM Tris/20 mM glycine pH 9.5, 5 mM MgCl 2 , 1 mM DTT, 200 mM NaCl, 250 μM H 2 PtePP, and 250 μM PABA or PAS and were allowed to proceed to completion as judged by LC-MS. FolC reactions contained (final concentrations) 1 μM FolC, 0.3 μM FolP1, 110 mM Tris/55 mM glycine pH 9.5, 11 mM MgCl 2 , 5 mM DTT, 200 mM KCl, 50 mM NaCl, 10% glycerol, 1 mM Lglutamate, 5 mM ATP, and 63 μM H 2 Pte or H 2 PtePAS. Aliquots were removed by autosampling at indicated timepoints and analyzed by LC-MS, using the above separation method. Substrate consumption and product formation were monitored through extracted ion counts (H 2 Pte m/z=315.1, H 2 Pte-Glu m/z=444.0, H 2 PtePAS m/z=331.1, H 2 PtePAS-Glu m/z=460.2). Relative intensities are calculated based on t=0 ion counts for substrates or the final timepoint ion counts for products.
FolP1 and FolC were >95% pure as judged by SDS-PAGE. Numbers denote drug concentration expressed in relation to MIC or, for APS and SNL, molar equivalent of SMX doses used. Color intensities correspond to relative levels are expressed as the log ratio of the normalized signal intensity in drug-treated cells at each concentration to the normalized signal intensity in the drug-free sample (n ≥ 2 independent experiments). Signal intensities were normalized to cell protein biomass at each concentration.
Fig. S3. A.
Extracted ion chromatograms and mass spectra (insets) corresponding to exemplary inactive biotransformation products of sulfonamide compounds, showing their compound and dose dependence (left, sulfanilamide; center, sulfamethoxazole; right, dapsone). Proposed structures, based on co-eluting in source fragmentation products described in Table S1 , are shown above each chromatogram. S5 . Metabolic pathway diagram of folate-dependent reactions. PABA (R= H, or PAS, R= OH) core structure highlighted in red. dfrA, dihydrofolate reductase; FGAR, phosphoribosyl-Nformylglycineamide; fmt, methionyltRNA formyltransferase; folD, methylene tetrahydrofolate dehydrogenase; GAR, glycineamide ribonucleotide; gcvT, glycine cleavage complex aminomethyltransferase; glyA, serine hydroxymethyltransferase; IMP, inosine monophosphate; metH, B12-dependent methionine synthase; metE, B12-independent methionine synthase; purN, 5-phosphoribosylglycinamide formyltransferase; purT, phosphoribosylglycinamide forymltransferase. Table S1 . Accurate mass-retention time pairs for specified biotransformation products, confirmed by co-elution with pure standards for N-Me-PAS, N-(Me)2-PAS, PAS-Pte, and, coeluting in source fragmentation products of proposed structures for reported sulfonamide biotransformation products (26) . 
